Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230945
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 1
---
 provided by the Alcon merger. If the Alcon merger agreement is not approved on October 23, it could be a deterrent to any future buyers and there is no guarantee that Alcon, who is the most logical buyer of this asset, would participate in any future process. We urge STAAR’s stockholders to vote ‘FOR’ the Alcon merger today.” STAAR Faces Sustained Challenges as a Standalone Company

| • |     | “Our immediate thought is that this [Alcon’s acquisition] is the best path forward for STAA as they                                                                                                                             
 were likely to struggle for some time given the dynamics in the broader Chinese economy. It was unlikely that STAA’s recent new mgmt. would be able to cut costs or rapidly grow their way out of STAA’s immediate challenges.” 
 – BTIG 8.5.25                                                                                                                                                                                                                   |

| • |     | “STAA reported ~$5.3M (-92% Y/Y) in Chinese revenue, down                                                                                                                                                    
 materially from $63.3M in 2Q24, as its two distributors burn through elevated inventory levels. STAA expects to have inventory levels align by 3Q25 with in-market procedure volume, as global macroeconomic 
 conditions improve, but given commentary from many companies out of China we’re less certain that this may be the case.” – BTIG 8.6.25                                                                       |

| • |     | “STAA’s 4Q24 results and initial 2025 outlook showed a major deterioration in the China business,  
 driven by excess channel inventory, and a challenging China macro environment.” – Jefferies 8.6.25 |

A Competing Proposal for STAAR is Unlikely. Other than Alcon, STAAR Has Not Received Any Acquisition or Merger Proposal for More than 10 Years

| • |     | “Given it is a merger, and we don’t foresee any regulatory problem or another bidder, our estimate is 
 that this deal is likely to be completed.” – Canaccord Genuity 8.5.25                                 |

| • |     | “Healthy premium limits risk of                                                                                                                               
 over-the-top bid…we see the ~5.9x proposed exit multiple as sufficiently fair and rich enough to limit risk of an over-the-top counteroffer.” – Mizuho 8.5.25 |

| • |     | “we think it is unlikely that higher bid will emerge given the multiple paid and the moving pieces with the